Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 51ºÚÁϳԹÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Alzheimer’s disease (AD) is a metabolic neurodegenerative disease featured by cerebrovascular dysfunction in addition to
cognitive decline. Amyloid β (Aβ) plaques followed by up-regulation of amyloid precursor protein (APP) and seladin-1
down-regulation, as well as insulin signaling impairment are associated with this disease. This study was designed to evaluate
the effect of insulin on Alzheimer’s signs induced by chronic hypoxia. 24 male rats were randomly divided into four groups:
control (C), sham (Sh), hypoxia (H), hypoxia + insulin (HI) and were exposed to hypoxic chamber (8% O2, 92% N2) for 30
days (four hours/day) in H and HI groups. Pro-inflammatory cytokines and insulin receptor substrate (IRS-1) in sera were
measured on day 30 after hypoxia period. Intranasal insulin administration was used as a neuroprotective and antidiabetic
drug. Spatial learning and memory were analyzed using the Morris water maze task. Amyloid precursor protein gene (APP)
and seladin-1 gene expression were studied in the hippocampus by real time-PCR. TNF-α, IL-1β and IRS-1 had significant
magnification in H group compared with C and Sh groups (p<0.05). Insulin improved Alzheimer’s signs such as seladin-1
fallen, APP risen gene expression and memory impairment. In conclusion, we indicate that chronic hypoxia mediates AD
pathogenesis and using insulin hormone as a neuroprotective and antidiabetic drug could be beneficial in neurodegenerative
damage induced by hypoxia.